# Safety and Efficacy of Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment Naive, HIV-1 and Hepatitis B Co-Infected Adults

> **NCT03547908** · PHASE3 · COMPLETED · sponsor: **Gilead Sciences** · enrollment: 244 (actual)

## Conditions studied

- HIV-1/HBV Co-Infection

## Interventions

- **DRUG:** B/F/TAF
- **DRUG:** Placebo to match DTG
- **DRUG:** Placebo to match F/TDF
- **DRUG:** DTG
- **DRUG:** F/TDF
- **DRUG:** Placebo to match B/F/TAF

## Key facts

- **NCT ID:** NCT03547908
- **Lead sponsor:** Gilead Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-05-30
- **Primary completion:** 2022-02-25
- **Final completion:** 2024-03-07
- **Target enrollment:** 244 (ACTUAL)
- **Last updated:** 2025-03-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03547908

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03547908, "Safety and Efficacy of Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment Naive, HIV-1 and Hepatitis B Co-Infected Adults". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT03547908. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*